EBMT 2021 | CARTITUDE-1: health-related QoL with cilta-cel for myeloma
Saad Usmani, MD, MBBS, MBA, Levine Cancer Institute and Atrium Health, Charlotte, NC, gives an update on the CARTITUDE-1 trial (NCT03548207) of ciltacabtagene autoleucel (cilta-cel) in patients with relapsed/refractory multiple myeloma, highlighting health-related quality of life (QoL) data. 95% of patients receiving cilta-cel experienced cytokine release syndrome (CRS) with 4% grade three of four, and neurotoxicity was observed in 20.6% of patients, with grade three of four in 9%. At a median follow-up of 12.4 months, the progression-free survival rate was 76.6% and overall survival rate was 88.5%. This interview took place during the 47th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT) 2021.
Disclosures
Saad Usmani, MD, MBBS, MBA, has received research funding from Amgen, Array Biopharma, BMS, Celgene, GSK, Janssen, Merck, Pharmacyclics, Sanofi, Seattle Genetics, SkylineDX and Takeda; has received consulting fees from Abbvie, Amgen, BMS, Celgene, GSK, Genentech/Roche, Janssen, Karyopharm, Merck, Oncopeptides, Sanofi, Seattle Genetics, SkylineDx and Takeda; and has received speaking fees from Celgene, Janssen, Sanofi and Takeda.
